Ressources et supports
Ressources et supports
Études cliniques
MoA et contrôle génétique
Awareness BRCA testing
Pour patients
Journal pour les patients traités par Lynparza
Événements
Aucun événement pour le moment.
Références
- Lynparza® 100 mg and 150 mg comprimés pelliculés, Résumé des caractéristiques du produit, version la plus récente
- https://ondpanon.riziv.fgov.be/SSPWebApplicationPublic/nl/Public/ProductSearch (accès 25/10/2021)
- O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547–560.
- Lord CJ and Ashworth A. PARP inhibitors: The first synthetic lethal targeted therapy. Science. 2017;355(6330):1152–1158.
- de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102.
- Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ Park JO, Hochhauser D, Arnold D, Oh DY, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-27.
- Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327 (Supplementary Appendix).
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.1.2020. ©National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Holter S et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33(28):3124–3129.
- Hu C et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401–2409.
NS ID BE-2720-Revision date 03/2022-WEB Local code 317